A. Moreno

Low neutralizing activity of AZD7442 against current SARS-CoV-2 Omicron variants in patients with B-cell malignancies

M. Dhodapkar, R. Ahmed, M. Suthar, 2023, Blood Advances.

Broadly neutralizing antibodies against sarbecoviruses generated by immunization of macaques with an AS03-adjuvanted COVID-19 vaccine

B. Pulendran, R. Baric, D. Veesler, 2023, Science Translational Medicine.

Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster

D. Douek, Sucheta Godbole, N. Rouphael, 2022, The New England journal of medicine.

Preclinical efficacy, safety, and immunogenicity of PHH-1V, a second-generation COVID-19 vaccine candidate based on a novel recombinant RBD fusion heterodimer of SARS-CoV-2

J. Barretina, B. Clotet, J. Segalés, 2021 .

Extremely potent pan-sarbecovirus neutralizing antibodies generated by immunization of macaques with an AS03-adjuvanted monovalent subunit vaccine against SARS-CoV-2

B. Pulendran, R. Baric, D. Veesler, 2023, bioRxiv.

Preclinical efficacy, safety, and immunogenicity of a COVID-19 vaccine candidate based on a recombinant RBD fusion heterodimer of SARS-CoV-2

J. Barretina, B. Clotet, J. Segalés, 2022 .

Preclinical evaluation of a COVID-19 vaccine candidate based on a recombinant RBD fusion heterodimer of SARS-CoV-2

J. Barretina, B. Clotet, J. Segalés, 2021, bioRxiv.

Impaired SARS-CoV-2 variant neutralization and CD8+ T cell responses following 3 doses of mRNA vaccines in myeloma: correlation with breakthrough infections.

A. Sette, C. Hofmeister, S. Lonial, 2022, Blood cancer discovery.